Aesica Appointment to Drive Service in Europe and Achieve Further Growth
Aesica has appointed two senior business development positions. Detlef Behrens has been appointed to the role of Vice President, Business Development, Finished Dose with Sven Wrabletz joining as Business Development Director, Finished Dose. Detlef has overall responsibility for business development and for finished dose services, covering formulation development, bulk manufacturing and packaging with a full international remit across the Group. Sven is also responsible for finished dose development, manufacturing and packaging but with a geographic remit covering Northern Germany, Benelux and Eastern Europe. Both positions are based in Germany. Detlef reports directly to Ian Muir, Managing Director, Finished Dose and prior to working for Aesica, Detlef held senior BD roles at Piramal and Next Pharma. As a qualified pharmacist he holds a PhD, and is a Board member and member of the Education Committee of DCAT.
Sven Wrabletz reports to Detlef Behrens, holds a Diplom-Betriebswirt (FH) and a Bachelor of Arts in International Business Administration and joined Aesica from Clondalkin, a packaging specialist.
Commenting on the new appointments, Ian Muir, Managing Director, Finished Dose remarked: “We are very pleased that Sven Wrabletz and Detlef Behrens have joined Aesica and look forward to the strong contribution that they are set to make to generate new business growth internationally, both in terms of sales and portfolio expansion.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.